Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
This article was originally published in RPM Report
Executive Summary
FDA's drug review managers and staff are showing signs of wear and tear from the tough political climate for the agency. Some key staff have departed. Merck took advantage of the turmoil to get a manager with knowledge of the endocrine area, where the taranabant NDA will be filed.